US20180141984A1 - Antimicrobial peptide analogues derived from abalone (haliotis discus) and antimicrobial pharmaceutical composition containing the same - Google Patents
Antimicrobial peptide analogues derived from abalone (haliotis discus) and antimicrobial pharmaceutical composition containing the same Download PDFInfo
- Publication number
- US20180141984A1 US20180141984A1 US15/364,398 US201615364398A US2018141984A1 US 20180141984 A1 US20180141984 A1 US 20180141984A1 US 201615364398 A US201615364398 A US 201615364398A US 2018141984 A1 US2018141984 A1 US 2018141984A1
- Authority
- US
- United States
- Prior art keywords
- peptide analogue
- antimicrobial
- antimicrobial peptide
- present disclosure
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000044503 Antimicrobial Peptides Human genes 0.000 title claims abstract description 98
- 108700042778 Antimicrobial Peptides Proteins 0.000 title claims abstract description 98
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 96
- 230000000845 anti-microbial effect Effects 0.000 title claims abstract description 62
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 12
- 241001489139 Haliotis discus Species 0.000 title description 7
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 67
- 150000001413 amino acids Chemical class 0.000 claims abstract description 16
- 239000004599 antimicrobial Substances 0.000 claims abstract description 12
- 241000588724 Escherichia coli Species 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 28
- 239000004480 active ingredient Substances 0.000 claims description 21
- 125000001165 hydrophobic group Chemical group 0.000 claims description 21
- 241000894006 Bacteria Species 0.000 claims description 17
- 241000222122 Candida albicans Species 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 13
- 125000000539 amino acid group Chemical group 0.000 claims description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 9
- 239000004472 Lysine Substances 0.000 claims description 9
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 9
- 239000006210 lotion Substances 0.000 claims description 9
- 235000014469 Bacillus subtilis Nutrition 0.000 claims description 8
- 241000186427 Cutibacterium acnes Species 0.000 claims description 8
- 241000607762 Shigella flexneri Species 0.000 claims description 8
- 241000191963 Staphylococcus epidermidis Species 0.000 claims description 8
- 241000194019 Streptococcus mutans Species 0.000 claims description 8
- 241000607272 Vibrio parahaemolyticus Species 0.000 claims description 8
- 229940055019 propionibacterium acne Drugs 0.000 claims description 8
- 241000192125 Firmicutes Species 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 244000063299 Bacillus subtilis Species 0.000 claims description 5
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 5
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 5
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims description 5
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 5
- 235000004279 alanine Nutrition 0.000 claims description 5
- 229940095731 candida albicans Drugs 0.000 claims description 5
- 239000006260 foam Substances 0.000 claims description 5
- 239000000443 aerosol Substances 0.000 claims description 4
- 239000003674 animal food additive Substances 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 4
- 239000002778 food additive Substances 0.000 claims description 4
- 239000002674 ointment Substances 0.000 claims description 4
- 208000035473 Communicable disease Diseases 0.000 claims description 3
- 208000015181 infectious disease Diseases 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000012528 membrane Substances 0.000 abstract description 19
- 230000002949 hemolytic effect Effects 0.000 abstract description 18
- 230000035699 permeability Effects 0.000 abstract description 13
- 230000002829 reductive effect Effects 0.000 abstract description 2
- 101001014217 Morone saxatilis Moronecidin Proteins 0.000 description 25
- 238000000034 method Methods 0.000 description 17
- 230000000844 anti-bacterial effect Effects 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- 125000003275 alpha amino acid group Chemical group 0.000 description 14
- 235000001014 amino acid Nutrition 0.000 description 13
- 239000012634 fragment Substances 0.000 description 13
- 244000005700 microbiome Species 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000001420 bacteriolytic effect Effects 0.000 description 9
- 210000003743 erythrocyte Anatomy 0.000 description 9
- 239000001974 tryptic soy broth Substances 0.000 description 9
- 108010050327 trypticase-soy broth Proteins 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 230000002147 killing effect Effects 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 239000008213 purified water Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 210000004899 c-terminal region Anatomy 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000003205 fragrance Substances 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 229920000936 Agarose Polymers 0.000 description 5
- 230000002421 anti-septic effect Effects 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 235000011187 glycerol Nutrition 0.000 description 5
- 238000010983 kinetics study Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- KUWPCJHYPSUOFW-YBXAARCKSA-N 2-nitrophenyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CC=CC=C1[N+]([O-])=O KUWPCJHYPSUOFW-YBXAARCKSA-N 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- -1 polyoxyethylene Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 241000894007 species Species 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 241000548230 Crassostrea angulata Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- 241001481825 Morone saxatilis Species 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 102000005936 beta-Galactosidase Human genes 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 239000008177 pharmaceutical agent Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 229920002545 silicone oil Polymers 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- 239000004034 viscosity adjusting agent Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 102000018389 Exopeptidases Human genes 0.000 description 1
- 108010091443 Exopeptidases Proteins 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- 240000006982 Guaiacum sanctum Species 0.000 description 1
- 235000004440 Guaiacum sanctum Nutrition 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241000237502 Ostreidae Species 0.000 description 1
- 241000269978 Pleuronectiformes Species 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000002862 amidating effect Effects 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000003593 chromogenic compound Substances 0.000 description 1
- 230000005757 colony formation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 235000008446 instant noodles Nutrition 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 229940041476 lactose 100 mg Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000001035 methylating effect Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 229940055577 oleyl alcohol Drugs 0.000 description 1
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020636 oyster Nutrition 0.000 description 1
- 230000002465 palmitoylating effect Effects 0.000 description 1
- 230000026792 palmitoylation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N63/00—Biocides, pest repellants or attractants, or plant growth regulators containing microorganisms, viruses, microbial fungi, animals or substances produced by, or obtained from, microorganisms, viruses, microbial fungi or animals, e.g. enzymes or fermentates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/34635—Antibiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/34—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals
- A23L3/3454—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by treatment with chemicals in the form of liquids or solids
- A23L3/3463—Organic compounds; Microorganisms; Enzymes
- A23L3/3526—Organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/046—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/007—Preparations for dry skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present disclosure relates to an antimicrobial peptide analogue derived from abalone ( Haliotis discus ) and an antimicrobial pharmaceutical composition containing the same.
- hdMolluscidin is an antimicrobial peptide consisting of 46 amino acids with a molecular weight of 4767.2 Da, purified from the gill of abalone ( Haliotis discus ). It is an antimicrobial peptide which exhibits little hemolytic activity and exhibits strong antimicrobial activity against Gram positive and Gram negative bacteria but no activity against C. albicans. In order to overcome the limited activity of hdMolluscidin and the limitation caused by the length of 46 amino acids, it is necessary to design and develop a new antimicrobial peptide such as an analogue with a fragmented length and increased antimicrobial activity.
- the antimicrobial peptide plays an important role as one of effective defense mechanisms against external sources of infection in the gill and mantle of oyster and sea mussel.
- This result suggests that the gill and mantle are organs which play an important role in the immune mechanism of shellfish, as a primary defense against external environments, and they are important targets in the search and purification of substances having antimicrobial activity.
- Korean Patent Registration No. 10-1384578 (patent document 1) relates to an antimicrobial peptide having a novel amino acid sequence, more particularly to an antimicrobial peptide isolated from abalone, which has antimicrobial activity against E. coli or Staphylococcus aureus.
- the patent document 1 does not disclose an antimicrobial peptide analogue derived from abalone which is commercially viable because it is composed of 15 or less amino acids and exhibits stronger antimicrobial activity against various bacteria.
- Patent document 1 Korean Patent Registration No. 10-1384578.
- the present disclosure is directed to designing and providing an antimicrobial peptide analogue using hdMolluscidin, a peptide derived from abalone ( Haliotis discus ) and has superior antimicrobial activity, which has a decreased number of amino acids to a commercially viable level and exhibits superior antimicrobial activity.
- the present disclosure provides an antimicrobial peptide analogue containing: a hydrophobic group containing 1-3 amino acid residues selected from alanine (A), leucine (L) and tryptophan (W); and a hydrophilic group containing 1 or 2 lysine (K) residue(s), wherein 3 or 4 of the hydrophobic group and 2 or 3 of the hydrophilic group are bound alternatingly.
- a hydrophobic group containing 1-3 amino acid residues selected from alanine (A), leucine (L) and tryptophan (W); and a hydrophilic group containing 1 or 2 lysine (K) residue(s), wherein 3 or 4 of the hydrophobic group and 2 or 3 of the hydrophilic group are bound alternatingly.
- the peptide analogue may form an ⁇ -helix structure.
- the peptide analogue may consist of 8-15 amino acid residues.
- the peptide analogue may contain at least one amino acid sequence KLLK.
- the hydrophobic group is located between the hydrophilic group and the at least one hydrophilic group bound to the hydrophobic group comprises 2 lysine (K) residues, the number of amino acid residues of the hydrophobic group may be 2.
- the peptide analogue may have an amino acid sequence selected from a group consisting of SEQ ID NOS 1-11.
- the antimicrobial peptide analogue may have an amidated or methylated C-terminal.
- the antimicrobial peptide analogue may have an acetylated or palmitoylated N-terminal.
- the peptide analogue may have antimicrobial activity against at least one selected from a group consisting of Gram positive bacteria, Gram negative bacteria and yeast.
- the peptide analogue may have antimicrobial activity against at least one selected from a group consisting of Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus mutans, Propionibacterium acnes, E. coli D31, E. coli ML35p, Shigella flexneri, Pseudomonas aeruginosa, Vibrio parahaemolyticus and Candida albicans.
- the present disclosure provides an antimicrobial pharmaceutical composition containing the antimicrobial peptide analogue as an active ingredient.
- the present disclosure provides a pharmaceutical composition for preventing and treating an infectious disease caused by bacteria, which contains the antimicrobial peptide analogue as an active ingredient.
- the present disclosure provides an antimicrobial cosmetic composition containing the antimicrobial peptide analogue as an active ingredient.
- the cosmetic composition may be in the form of a solution, a powder, an emulsion, a lotion, a spray, an ointment, an aerosol, a cream or a foam.
- the present disclosure provides an antimicrobial food additive containing the antimicrobial peptide analogue as an active ingredient.
- the present disclosure provides a feed additive containing the antimicrobial peptide analogue as an active ingredient.
- the present disclosure provides a hygiene product containing the antimicrobial peptide analogue as an active ingredient.
- the antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
- FIG. 1 shows a sequence alignment result of the amino acid sequences of hdMolluscidin, an antimicrobial peptide derived from abalone, and cgMolluscidin, an antimicrobial peptide derived from Pacific oyster.
- FIG. 2 shows the amino acid sequences of hdMolluscidin, an antimicrobial peptide derived from abalone, and a parent peptide portion (fragment 1 and fragment 2) for designing the antimicrobial peptide analogue according to the present disclosure.
- FIG. 2 shows that the peptide analogue forms an ⁇ -helix structure.
- FIG. 3 shows the antimicrobial activity of an antimicrobial peptide analogue according to the present disclosure.
- FIGS. 4A and 4B show a result of measuring the hemolytic activity of an antimicrobial peptide analogue according to the present disclosure and piscidin 1 against human red blood cells.
- FIGS. 5A and 5B show a result of measuring the membrane permeability of an antimicrobial peptide analogue according to the present disclosure and piscidin 1 for E. coli.
- FIG. 6 shows a chromogenic bacteriolytic plate assay result of an antimicrobial peptide analogue according to the present disclosure.
- FIGS. 7A, 7B and 7C show a result of measuring the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of an antimicrobial peptide analogue according to the present disclosure and piscidin 1 for E. coli.
- MIC minimum inhibitory concentration
- MMC minimum bactericidal concentration
- FIGS. 8A and 8B show a result of killing kinetics study of an antimicrobial peptide analogue according to the present disclosure and piscidin 1 at 1 ⁇ MIC and 5 ⁇ MIC for E. coli.
- the inventors of the present disclosure have made consistent efforts to develop an antimicrobial peptide analogue derived from abalone ( Haliotis discus ), which has superior antimicrobial activity and is commercially viable, and have completed the present disclosure as a result thereof.
- the antimicrobial peptide analogue according to the present disclosure contains: a hydrophobic group containing 1-3 amino acid residues selected from alanine (A), leucine (L) and tryptophan (W); and a hydrophilic group containing 1 or 2 lysine (K) residue(s), wherein 3 or 4 of the hydrophobic group and 2 or 3 of the hydrophilic group are bound alternatingly.
- the peptide analogue according to the present disclosure is derived from a peptide (hdMolluscidin) which has been extracted and purified from the gill of abalone ( Haliotis discus ).
- hdMolluscidin is a peptide having a very superior antimicrobial activity.
- hdMolluscidin is not commercially viable because it consists of a total of 46 amino acids. Therefore, the inventors of the present disclosure have developed an antimicrobial peptide analogue derived from hdMolluscidin, which is a peptide derived from abalone, which has superior antimicrobial activity and is commercially viable.
- the antimicrobial peptide analogue according to the present disclosure may form an ⁇ -helix structure.
- the peptide analogue forms an ⁇ -helix structure when it exhibits amphiphilicity with hydrophilicity and hydrophobicity at the same time.
- the hydrophilic part improves binding force and the hydrophobic part improves permeability.
- the inventors of the present disclosure have predicted the secondary structure of hdMolluscidin using a secondary structure prediction program for designing of the peptide analogue.
- the predicted secondary structure of hdMolluscidin was a combination of a random coil structure, an ⁇ -helix structure and a ⁇ -sheet structure. Based on the predicted secondary structure, the part of hdMolluscidin with an amphiphilic ⁇ -helix structure was selected because it is known as the ideal structure in exhibiting antimicrobial activity. And, the N-terminal part of hdMolluscidin was selected as a parent peptide portion for designing the analogue.
- FIG. 2 shows the amino acid sequences of hdMolluscidin, an antimicrobial peptide derived from abalone, and the parent peptide portion (fragment 1 and fragment 2) for designing the antimicrobial peptide analogue according to the present disclosure.
- each of the fragment 1 (amino acid sequence: AATKPKKAGAEAAP) and the fragment 2 (amino acid sequence: KPAKKQTKKKP) does not exhibit amphiphilicity although it forms an ⁇ -helix structure, it is necessary to substitute some amino acids so that it can exhibit both hydrophobicity and hydrophilicity at the same time.
- the hydrophilic part facilitates binding to the cell membrane or DNA and the hydrophobic part facilitates permeation.
- lysine (K) which is a hydrophilic (positively charged) residue
- alanine (A) which is a hydrophobic residue
- proline (P), threonine (T) and glutamine (Q), which are polar but not electrically charged may be substituted with another hydrophobic residue, specifically a leucine (L) residue, because they are not desired in terms of antimicrobial activity.
- tryptophan (W) which exhibits high membrane permeability and high resistance to proteases, may be located beside a residue vulnerable to the enzymes such as lysine (K) so as to reduce cutting by the proteases.
- the antimicrobial peptide analogue of the present disclosure is designed using the fragment 1 or the fragment 2 as a parent peptide and may contain: a hydrophobic group containing 1-3 amino acid residues selected from alanine (A), leucine (L) and tryptophan (W); and a hydrophilic group containing 1 or 2 lysine (K) residue(s).
- the number of the hydrophobic group may be 3 or 4 and the number of the hydrophilic group may be 2 or 3.
- the hydrophobic group may be bound to 2 or more locations selected from a group consisting of the C-terminal and the N-terminal of the hydrophilic group and between hydrophilic groups.
- the hydrophobic group may consist of 2 or less kinds of amino acid residues.
- the antimicrobial peptide analogue according to the present disclosure may consist of 8-15 amino acid residues. And, specifically, it may contain at least one amino acid sequence KLLK. If the peptide analogue contains the amino acid sequence ‘KLLK’, it is very advantageous in enhancing antimicrobial activity.
- the hydrophobic group is located between the hydrophilic group and the at least one hydrophilic group bound to the hydrophobic group comprises 2 lysine (K) residues, the number of amino acid residues of the hydrophobic group may be 2.
- an amino group (—NH 2 ) or a methyl group (—CH 3 ) may be added to the C-terminal of the antimicrobial peptide analogue according to the present disclosure. If the C-terminal of the antimicrobial peptide analogue is amidated, resistance to proteases and positive net charge may be further enhanced. And, if it is methylated, in-vivo stability may be increased because resistance to exopeptidases, which cleave the peptide from the terminal, can be increased.
- the peptide analogue may have an acetylated or palmitoylated N-terminal. If the N-terminal of the antimicrobial peptide analogue is acetylated, much superior antimicrobial activity can be achieved as compared to when it is not and the peptide can be protected from proteolytic degradation. And, if it is palmitoylated, permeability into cells can be enhanced.
- the antimicrobial peptide analogue according to the present disclosure exhibits antimicrobial activity and is commercially viable because it has a short amino acid sequence.
- the antimicrobial peptide analogue according to the present disclosure has strong inner membrane permeability. That is to say, it is likely that the antimicrobial peptide analogue according to the present disclosure exhibits antimicrobial activity by directly permeating into the inner membrane of bacteria.
- the antimicrobial peptide analogue according to the present disclosure lacks a cytotoxicity problem because it exhibits no hemolytic activity.
- the antimicrobial peptide analogue designed and prepared as described above may have antimicrobial activity against one or more selected from a group consisting of bacteria such as Gram positive bacteria, Gram negative bacteria, etc. and fungi such as yeast, molds, etc.
- the antimicrobial peptide analogue may have antimicrobial activity against one or more selected from a group consisting of four species of Gram positive bacteria ( Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus mutans and Propionibacterium acnes ), five species of Gram negative bacteria ( E. coli D31, E. coli ML35p, Shigella flexneri, Pseudomonas aeruginosa and Vibrio parahaemolyticus ) and one yeast species ( Candida albicans ).
- Gram positive bacteria Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus mutans and Propionibacterium acnes
- five species of Gram negative bacteria E. coli D31, E. coli ML35p, Shigella flexneri, Pseudomonas aeruginosa and Vibrio parahaemolyticus
- yeast species Candida albicans
- the present disclosure also provides an antimicrobial pharmaceutical composition containing the antimicrobial peptide analogue according to the present disclosure as an active ingredient.
- a method for administering the pharmaceutical composition is not particularly limited. Specifically, it may be administered intraarterially, intravenously, subcutaneously, intrarectally, intranasally or via any other parenteral route. More specifically, it may be administered intraarterially, intravenously, orally or directly into muscle cells.
- the administration dosage of the composition will rely on the activity of the active ingredient, administration route, severity of the condition to be treated, condition and previous disease history of the patient. However, to start with a lower dosage than is required to achieve the desired therapeutic effect and gradually increase the administration dosage until the desired effect is achieved is within the knowledge of the related art and the specific administration dosage may be determined considering the age, sex, body type and body weight.
- the composition may be further processed before being formulated into a pharmaceutically acceptable pharmaceutical agent. Specifically, it may be pulverized or ground into smaller particles.
- an effective dosage of the antimicrobial peptide of the present disclosure may be 1-2 mg/kg, specifically 0.5-1 mg/kg, and the administration may be made 1-3 times a day. However, the scope of the present disclosure is not limited by the administration dosage by any means.
- the pharmaceutical composition of the present disclosure may be prepared into a formulation of a unit dosage form or a multiple dosage form using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily employed by one of ordinary skill in the art to which the present disclosure belongs.
- the formulation may be an oral formulation such as a powder, a granule, a tablet, a capsule, a suspension, an emulsion, a syrup, an aerosol, etc., a formulation for external application such as an ointment, a cream, etc. or any other pharmaceutical formulation such as a suppository, a sterile solution for injection, etc. and may further contain a dispersant or a stabilizer.
- the antimicrobial peptide analogue exhibits antimicrobial activity against Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus mutans, Propionibacterium acnes, E. coli D31, E. coli ML35p, Shigella flexneri, Pseudomonas aeruginosa, Vibrio parahaemolyticus and Candida albicans, it can prevent or treat the diseases caused by them, such as food poisoning, candidiasis, typhoid, cholera, etc. Therefore, the antimicrobial peptide analogue may be used as an active ingredient in a pharmaceutical composition for preventing or treating the infectious diseases caused by the microorganisms.
- the antimicrobial peptide analogue may also be used as an active ingredient of an antimicrobial cosmetic composition.
- the cosmetic composition may be in the form of a solution, a powder, an emulsion, a lotion, a spray, an ointment, an aerosol, a cream or a foam.
- the cosmetic composition of the present disclosure may contain a carrier which is acceptable in a cosmetic formulation.
- carrier which is acceptable in a cosmetic formulation refers to a compound or composition already used in cosmetic formulations or a compound or composition to be developed which lacks toxicity, instability or irritability as to be applicable to human skin.
- the carrier may be contained in an amount of about 1-99.99 wt %, specifically about 90-99.99 wt %, based on the total weight of the cosmetic composition of the present disclosure.
- the carrier may include an alcohol, an oil, a surfactant, a fatty acid, a silicone oil, a humectant, a moisturizer, a viscosity modifier, an emulsifier, a stabilizer, a sunscreen, a UV absorbent, a colorant, a fragrance, etc.
- a compound or composition that can be used as the alcohol, oil, surfactant, fatty acid, silicone oil, humectant, moisturizer, viscosity modifier, emulsifier, stabilizer, sunscreen, UV absorbent, colorant or fragrance is known in the art and can be adequately selected by those skilled in the art.
- the cosmetic composition according to the present disclosure may contain, in addition to the peptide analogue, glycerin, butylene glycol, propylene glycol, polyoxyethylene hydrogenated castor oil, ethanol, triethanolamine, etc. and may contain a trace amount of an antiseptic, a fragrance, a colorant, purified water, etc., if necessary.
- the term skin includes not only the face but also the scalp and the whole body.
- the cosmetic composition may be prepared as a shampoo, a rinse, a treatment, a hair restorer, etc. And, for application to the whole body, it may be prepared as a body cleanser, etc.
- the antimicrobial peptide analogue may also be used as an active ingredient of an antimicrobial food additive or a feed additive.
- the antimicrobial peptide according to the present disclosure can be usefully used in an antimicrobial food additive or a feed additive because it has superior antimicrobial activity against not only Gram negative and Gram positive bacteria but also fungi and lacks cytotoxicity.
- the food is not particularly limited in its kind.
- examples of the food to which the substance can be added include a drink, a meat, a sausage, a bread, a biscuit, a rice cake, a chocolate, a candy, a snack, a pizza, an instant noodle, a noodle, a gum, a diary product including ice cream, a soup, a beverage, an alcoholic beverage, a vitamin supplement and any health functional food.
- the antimicrobial peptide analogue of the present disclosure may be added to a food as it is or as being mixed with other food or food ingredients. The mixing amount of the active ingredient may be determined adequately depending on the purpose of use (for prevention or improvement).
- the antimicrobial peptide analogue may be added in an amount of 0.1-20 wt % based on the total weight of the food.
- the amount of the active ingredient may be smaller than the above-described range.
- the amount of the active ingredient may be larger than the above-described range because it has no safety problem.
- the antimicrobial peptide analogue may be usefully used as an active ingredient of a hygiene product such as a wet wipe, a hand sanitizer, a mouthwash, an oral antiseptic or a toothpaste additive.
- Tryptic soy broth (TSB) and agarose type I (low EEO agar) for measurement of antimicrobial activity were purchased from Merck (Darmstadt, Germany) and Sigma (St. Louis, Mo, USA), respectively.
- Water and acetonitrile (CH 3 CN) for HPLC used in purification were purchased from Tedia (Ohio, USA). All other reagents were of analytical grade.
- the designed analogues consisted of 8-15 amino acids. They were designed through amidation or methylation at the C-terminal, acetylation or palmitoylation at the N-terminal or addition, substitution, removal, etc. of amino acids at specific locations.
- the designed peptide analogues were synthesized and purified by Peptron Inc. (Daejeon, Korea) to a purity of 95% or higher.
- the analogues were synthesized by F-moc solid-phase synthesis using the peptide synthesizer ASP48S (Peptron, Daejeon, Korea) and purified by RP-HPLC using the Shiseido Capcell-Pak C18 column (250 mm ⁇ 4.6 mm, 10 ⁇ m).
- the purification was conducted at 220 nm with a flow rate of 1 mL/min using a H 2 O—CH 3 CN solvent system containing 0.1% (v/v) trifluoroacetic acid with a concentration gradient of 3-40%.
- the molecular weight of the purified peptide analogues was measured by liquid chromatography/mass spectrometry (LC/MS; HP1100 series; Agilent, Santa Clara, Calif., USA).
- the purified peptide analogues were dissolved in 0.01% acetic acid to a concentration of 1000 ⁇ g/mL and used in the following experiments.
- Gram positive bacteria Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus mutans and Propionibacterium acnes
- Gram negative bacteria E. coli D31, E. coli ML35p, Shigella flexneri, Pseudomonas aeruginosa and Vibrio parahaemolyticus
- yeast species Candida albicans
- the antimicrobial activity was measured by ultrasensitive radial diffusion assay (URDA) using two layers of media of different concentrations.
- URDA ultrasensitive radial diffusion assay
- the microorganisms were pre-cultured in each medium for 18 hours and the concentration of the microorganisms was adjusted to 84% T ( ⁇ 1 ⁇ 10 8 CFU/mL) using a colorimeter (Product No. 52-1210, BioMerieux, Inc., USA). Then, 0.5 mL of the diluted microorganism solution was added to an underlay gel containing 9.5 mL of 0.03% TSB, 1% type I agarose and 10 mM phosphate buffer (PB; pH 6.5) and plated and solidified on a plate after mixing well. After boring a well with a diameter of 2.5 mm on the solidified plate using a punch, 5 ⁇ L of each analogue solution was introduced.
- PB mM phosphate buffer
- Hemolytic activity was measured using human red blood cells. After adding to human blood an equal amount of phosphate buffered saline (PBS, 50 mM sodium phosphate, 150 mM NaCl, pH 7.4), mixing and centrifuging at 8000 ⁇ g and 4° C. for 1 minute, the supernatant was removed and the remaining red blood cells were washed 3 times. The red blood cells were added to PBS to a concentration of 3% hematocrit. In order to measure the hemolytic activity, 90 ⁇ L of the 3% hematocrit was introduced to an e-tube and then 10 ⁇ L of each analogue solution ( ⁇ 10) was added. After incubation of each e-tube at 37° C.
- PBS phosphate buffered saline
- the inner membrane permeability was measured by measuring the activity of ⁇ -galactosidase present in the cytoplasm of E. coli ML35p using O-nitrophenyl- ⁇ -D-galactopyranoside (ONPG) as a non-membrane-permeative chromogenic substrate.
- Cultured E. coli ML35p in the mid-logarithmic phase was washed with 10 mM sodium phosphate buffer (NaPB, pH 7.4) and then dissolved in the same buffer containing 1.5 mM ONPG. Then, after adding the peptide analogue, the degree of hydrolysis of ⁇ -galactosidase released from the E. coli ML35p by the ONPG to O-nitrophenol was measured at 420 nm. Piscidin 1 and 0.01% acetic acid were used as control groups.
- chromogenic bacteriolytic plate assay was conducted using E. coli ML35p containing a chromosomal IPTG-inducible ⁇ -galactosidase gene (Mardones, G., Venegas, A. Chromogenic plate assay distinguishing bacteriolytic from bacteriostatic activity of an antibiotic agent. J Microbiol Methods. 2000, 40(3), 199-206). After inoculating 2 mL of E. coli ML35p to TSB and culturing at 37° C.
- the minimum inhibitory concentration of the analogues was measured according to Patrzykat et al.'s method (Patrzykat, A., Gallant, J. W., Seo, J. K., Pytyck, J., Douglas, S. E. Novel antimicrobial peptides derived from flatfish genes. Antimicrob Agents Chemother. 2003, 47(8), 2464-2470).
- the peptide analogue solutions were prepared by continuous dilution using 100 ⁇ g/mL to 3.13 ⁇ g/mL of 0.01% HAc and the measurement was made using 96-well polypropylene microtiter plates (Costar; Corning Incorporated, Corning, N.Y., USA).
- coli ML35p used for the measurement was cultured in TSB medium for 16 hours up to the mid-logarithmic phase and then finally diluted to a concentration of 10 6 CFU/mL using TSB medium.
- 90 ⁇ L of the finally diluted microorganism solution was added to each well of a 96-well plate and then 10 ⁇ L of each analogue solution at a concentration of ⁇ 10 of the target concentration was added to each well.
- No analogue was added for a negative control group and piscidin 1 was added for a positive control group.
- the minimum inhibitory concentration was defined as the concentration of the analogue when no growth of microorganisms was visually observed at all.
- each analogue corresponding to the minimum inhibitory concentration was taken from the microorganism solution of each well and plated on a TSA plate. After culturing, it was investigated whether the mechanism is bacteriostatic or bactericidal by based on colony formation.
- killing rate for each analogue was investigated at 1 ⁇ MIC and 5 ⁇ MIC for 60 minutes.
- the analogue was added to an e-tube containing 10 6 CFU/mL of E. coli ML35p. While incubating at 37° C., 10 ⁇ L of the solution was taken from the tube at predetermined times (5, 10, 20, 30, 40, 50 and 60 minutes after the addition of the analogue) and plated on a TSA plate. Then, the number of formed colonies was counted. As control groups, no analogue or piscidin 1 was added. The killing % for the analogues was represented as the number of formed colonies relative to that when no analogue was added.
- hdMolluscidin isolated from the gill of abalone ( Haliotis discus ), is an antimicrobial peptide consisting of 46 amino acids and having a molecular weight of 4767.2 Da.
- hdMolluscidin shows high sequence similarity to cgMolluscidin, an antimicrobial peptide derived from the gill of Pacific oyster ( FIG. 1 ).
- FIG. 1 shows a sequence alignment result of the amino acid sequences of hdMolluscidin and cgMolluscidin. In FIG. 1 , the conserved sequences are shown black.
- hdMolluscidin has a combination of ⁇ -helix and random structures ( FIG. 2 ). Based on this result, two portions (fragment 1 and fragment 2) toward the N-terminal exhibiting ⁇ -helix structure were selected as parent regions for designing analogues.
- the peptide analogues designed based on the ⁇ -helix structure of hdMolluscidin toward the N-terminal are shown in Table 1. Each analogue consisted of 8-15 amino acid residues. The synthesized analogues were identified by measuring molecular weight.
- the antimicrobial activity of the analogues and piscidin 1 (antimicrobial peptide derived from a hybrid striped bass) as a control antimicrobial peptide against bacteria and one yeast species was measured by the URDA method.
- the analogues of the present disclosure showed strong antimicrobial activity against the microorganisms.
- the antimicrobial peptide analogues having amino acid sequences of SEQ ID NO 4 (Ab2-5) and SEQ ID NO 10 (Ab4-7) showed the best antimicrobial activity ( FIG. 3 ).
- the antimicrobial peptide analogues of the present disclosure showed strong antimicrobial activity against C. albicans.
- aeruginosa KCTC2004 ⁇ 36.0 14.2 15.2 10.7 8.0
- aeruginosa KCTC2004 ⁇ 17.8 7.2 8.7 8.0 Vibrio parahaemolyticus 9.5 4.7 9.0 3.0 KCCM42264 C. albicans KCTC7965 Yeast 14.0 7.4 10.0 >62.5
- the hemolytic activity of the analogues and piscidin 1 as a control antimicrobial peptide against human red blood cells was measured.
- the peptide analogues of SEQ ID NO 4 and SEQ ID NO 10 showed good hemolytic activity ( FIG. 4 ).
- the peptide analogues of the present disclosure showed little hemolytic activity up to the concentration of 50 ⁇ g/mL.
- SEQ ID NO 4 (Ab2-5) showed about 10% of hemolytic activity
- SEQ ID NO 10 (Ab4-7) showed about 50% of hemolytic activity against human red blood cells.
- piscidin 1 showed strong hemolytic activity at 12.5 ⁇ g/mL. This result suggests that, unlike piscidin 1 which has strong hemolytic activity, the analogues of the present disclosure show little toxicity against human red blood cells at effective concentrations ( ⁇ 50 ⁇ g/mL).
- hdMolluscidin analogues of the present disclosure are likely to exhibit antimicrobial activity by directly permeating into the bacterial inner membrane.
- chromogenic bacteriolytic plate assay was conducted using E. coli ML35p containing a chromosomal IPTG- inducible ⁇ -galactosidase gene ( FIG. 6 ).
- the antibiotic streptomycin known to exhibit chromogenic bacteriolytic activity against E. coli ML35p showed a blue line at the edge portion
- tetracycline known not to exhibit bacteriolytic activity showed no blue line at the edge portion.
- Piscidin 1 used as a control substance showed an edge line and the peptide analogues of the present disclosure of SEQ ID NO 4 (Ab2-5) and SEQ ID NO 10 (Ab4-7) also showed bacteriolytic activity because blue lines were observed at the edge portion.
- MIC Minimum Inhibitory Concentration
- MCC Minimum Bactericidal Concentration
- MIC Minimum inhibitory concentration
- MBC minimum bactericidal concentration
- MBC minimum inhibitory concentration
- MBC Minimum bactericidal concentration
- MBC Minimum bactericidal concentration
- MBC Minimum bactericidal concentration
- the inventors of the present disclosure have designed and synthesized peptide analogues by solid-phase synthesis from hdMolluscidin, an antimicrobial peptide isolated from the gill of abalone.
- the peptide analogues of the present disclosure were prepared by selecting a parent region from the N-terminal of hdMolluscidin, applying substitution, addition or removal of amino acids and amidating or methylating the C-terminal and/or acetylating or palmitoylating the N-terminal.
- the peptide analogues of the present disclosure showed strong antimicrobial activity and exhibited little hemolytic activity for red blood cells at concentrations exhibiting antimicrobial activity.
- the analogues were demonstrated to directly bind to the membrane of bacteria and kill the bacteria by permeating into the inner membrane.
- the peptide analogues of the present disclosure are expected to be utilized as candidate substances for replacing existing antibiotics.
- Peptide analogue of the present disclosure 20 mg Lactose 20 mg
- a powder was prepared by mixing the above ingredients and filling in a sealed pouch.
- Peptide analogue of the present disclosure 10 mg Corn starch 100 mg Lactose 100 mg Magnesium stearate 2 mg
- a tablet was prepared by mixing the above ingredients and tableting according to a commonly employed method.
- Peptide analogue of the present disclosure 10 mg Crystalline cellulose 3 mg Lactose 14.8 mg Magnesium stearate 0.2 mg
- a capsule was prepared by mixing the above ingredients and filling in a gelatin capsule according to a commonly employed method.
- Peptide analogue of the present disclosure 20 mg Isomerized sugar 10 g Mannitol 5 g Purified water adequate
- the above ingredients were added to and dissolved in purified water and an adequate amount of lemon flavor was added. After making the final volume 100 mL by adding purified water, the resulting liquid was filled in a brown bottle and sterilized.
- Peptide analogue of the present disclosure 10 ⁇ g/mL Dilute HCl BP to pH 7.6 Sodium chloride BP up to 1 mL
- the peptide analogue of the present disclosure was dissolved in an adequate volume of sodium chloride BP. After adjusting the pH of the resulting solution to pH7.6 using dilute HCl BP, the final volume was adjusted using sodium chloride BR After sufficient mixing, the resulting solution was filled in a 5-mL type I ampoule and the ampoule was sealed by melting. Then, an injection was prepared by sterilizing the solution in an autoclave at 120° C. for at least 15 minutes.
- An antibacterial softening lotion containing the peptide analogue of the present disclosure was prepared according to a commonly employed method as described in [Table 5].
- An antibacterial nourishing lotion containing the peptide analogue of the present disclosure was prepared according to a commonly employed method as described in [Table 6].
- An antibacterial cleansing foam containing the peptide analogue of the present disclosure was prepared according to a commonly employed method as described in [Table 7].
- An antibacterial nourishing cream containing the peptide analogue of the present disclosure was prepared according to a commonly employed method as described in [Table 8].
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Husbandry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dispersion Chemistry (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Wood Science & Technology (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
Abstract
Description
- This application claims priority under 35 U.S.C. § 119 to Korean Patent Application No. 10-2016-0154215 filed on Nov. 18, 2016 in the Korean Intellectual Property Office, the disclosure of which is incorporated herein by reference in its entirety.
- The present disclosure relates to an antimicrobial peptide analogue derived from abalone (Haliotis discus) and an antimicrobial pharmaceutical composition containing the same.
- hdMolluscidin is an antimicrobial peptide consisting of 46 amino acids with a molecular weight of 4767.2 Da, purified from the gill of abalone (Haliotis discus). It is an antimicrobial peptide which exhibits little hemolytic activity and exhibits strong antimicrobial activity against Gram positive and Gram negative bacteria but no activity against C. albicans. In order to overcome the limited activity of hdMolluscidin and the limitation caused by the length of 46 amino acids, it is necessary to design and develop a new antimicrobial peptide such as an analogue with a fragmented length and increased antimicrobial activity.
- According to recent studies, it is reported that the antimicrobial peptide plays an important role as one of effective defense mechanisms against external sources of infection in the gill and mantle of oyster and sea mussel. This result suggests that the gill and mantle are organs which play an important role in the immune mechanism of shellfish, as a primary defense against external environments, and they are important targets in the search and purification of substances having antimicrobial activity. However, there has not been much effort in developing novel antimicrobial peptides therefrom.
- Korean Patent Registration No. 10-1384578 (patent document 1) relates to an antimicrobial peptide having a novel amino acid sequence, more particularly to an antimicrobial peptide isolated from abalone, which has antimicrobial activity against E. coli or Staphylococcus aureus. However, the
patent document 1 does not disclose an antimicrobial peptide analogue derived from abalone which is commercially viable because it is composed of 15 or less amino acids and exhibits stronger antimicrobial activity against various bacteria. -
Patent document 1. Korean Patent Registration No. 10-1384578. - The present disclosure is directed to designing and providing an antimicrobial peptide analogue using hdMolluscidin, a peptide derived from abalone (Haliotis discus) and has superior antimicrobial activity, which has a decreased number of amino acids to a commercially viable level and exhibits superior antimicrobial activity.
- In an aspect, the present disclosure provides an antimicrobial peptide analogue containing: a hydrophobic group containing 1-3 amino acid residues selected from alanine (A), leucine (L) and tryptophan (W); and a hydrophilic group containing 1 or 2 lysine (K) residue(s), wherein 3 or 4 of the hydrophobic group and 2 or 3 of the hydrophilic group are bound alternatingly.
- The peptide analogue may form an α-helix structure.
- The peptide analogue may consist of 8-15 amino acid residues.
- The peptide analogue may contain at least one amino acid sequence KLLK.
- If the hydrophobic group is located between the hydrophilic group and the at least one hydrophilic group bound to the hydrophobic group comprises 2 lysine (K) residues, the number of amino acid residues of the hydrophobic group may be 2.
- The peptide analogue may have an amino acid sequence selected from a group consisting of SEQ ID NOS 1-11.
- The antimicrobial peptide analogue may have an amidated or methylated C-terminal.
- The antimicrobial peptide analogue may have an acetylated or palmitoylated N-terminal.
- The peptide analogue may have antimicrobial activity against at least one selected from a group consisting of Gram positive bacteria, Gram negative bacteria and yeast.
- The peptide analogue may have antimicrobial activity against at least one selected from a group consisting of Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus mutans, Propionibacterium acnes, E. coli D31, E. coli ML35p, Shigella flexneri, Pseudomonas aeruginosa, Vibrio parahaemolyticus and Candida albicans.
- In another aspect, the present disclosure provides an antimicrobial pharmaceutical composition containing the antimicrobial peptide analogue as an active ingredient.
- In another aspect, the present disclosure provides a pharmaceutical composition for preventing and treating an infectious disease caused by bacteria, which contains the antimicrobial peptide analogue as an active ingredient.
- In another aspect, the present disclosure provides an antimicrobial cosmetic composition containing the antimicrobial peptide analogue as an active ingredient.
- The cosmetic composition may be in the form of a solution, a powder, an emulsion, a lotion, a spray, an ointment, an aerosol, a cream or a foam.
- In another aspect, the present disclosure provides an antimicrobial food additive containing the antimicrobial peptide analogue as an active ingredient.
- In another aspect, the present disclosure provides a feed additive containing the antimicrobial peptide analogue as an active ingredient.
- In another aspect, the present disclosure provides a hygiene product containing the antimicrobial peptide analogue as an active ingredient.
- The antimicrobial peptide analogue according to the present disclosure is designed based on hdMolluscidin which is a peptide derived from the gill of abalone and has been designed to be commercially viable by reducing the number of amino acids. Despite the reduced number of amino acids, the designed peptide analogue exhibits very superior antimicrobial activity as well as high membrane permeability and low hemolytic activity.
-
FIG. 1 shows a sequence alignment result of the amino acid sequences of hdMolluscidin, an antimicrobial peptide derived from abalone, and cgMolluscidin, an antimicrobial peptide derived from Pacific oyster. -
FIG. 2 shows the amino acid sequences of hdMolluscidin, an antimicrobial peptide derived from abalone, and a parent peptide portion (fragment 1 and fragment 2) for designing the antimicrobial peptide analogue according to the present disclosure.FIG. 2 shows that the peptide analogue forms an α-helix structure. -
FIG. 3 shows the antimicrobial activity of an antimicrobial peptide analogue according to the present disclosure. -
FIGS. 4A and 4B show a result of measuring the hemolytic activity of an antimicrobial peptide analogue according to the present disclosure andpiscidin 1 against human red blood cells. -
FIGS. 5A and 5B show a result of measuring the membrane permeability of an antimicrobial peptide analogue according to the present disclosure andpiscidin 1 for E. coli. -
FIG. 6 shows a chromogenic bacteriolytic plate assay result of an antimicrobial peptide analogue according to the present disclosure. -
FIGS. 7A, 7B and 7C show a result of measuring the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) of an antimicrobial peptide analogue according to the present disclosure andpiscidin 1 for E. coli. -
FIGS. 8A and 8B show a result of killing kinetics study of an antimicrobial peptide analogue according to the present disclosure andpiscidin 1 at 1×MIC and 5×MIC for E. coli. - The inventors of the present disclosure have made consistent efforts to develop an antimicrobial peptide analogue derived from abalone (Haliotis discus), which has superior antimicrobial activity and is commercially viable, and have completed the present disclosure as a result thereof.
- Specifically, the antimicrobial peptide analogue according to the present disclosure contains: a hydrophobic group containing 1-3 amino acid residues selected from alanine (A), leucine (L) and tryptophan (W); and a hydrophilic group containing 1 or 2 lysine (K) residue(s), wherein 3 or 4 of the hydrophobic group and 2 or 3 of the hydrophilic group are bound alternatingly.
- The peptide analogue according to the present disclosure is derived from a peptide (hdMolluscidin) which has been extracted and purified from the gill of abalone (Haliotis discus). hdMolluscidin is a peptide having a very superior antimicrobial activity. However, hdMolluscidin is not commercially viable because it consists of a total of 46 amino acids. Therefore, the inventors of the present disclosure have developed an antimicrobial peptide analogue derived from hdMolluscidin, which is a peptide derived from abalone, which has superior antimicrobial activity and is commercially viable.
- The antimicrobial peptide analogue according to the present disclosure may form an α-helix structure. The peptide analogue forms an α-helix structure when it exhibits amphiphilicity with hydrophilicity and hydrophobicity at the same time. The hydrophilic part improves binding force and the hydrophobic part improves permeability.
- First, the inventors of the present disclosure have predicted the secondary structure of hdMolluscidin using a secondary structure prediction program for designing of the peptide analogue. The predicted secondary structure of hdMolluscidin was a combination of a random coil structure, an α-helix structure and a β-sheet structure. Based on the predicted secondary structure, the part of hdMolluscidin with an amphiphilic α-helix structure was selected because it is known as the ideal structure in exhibiting antimicrobial activity. And, the N-terminal part of hdMolluscidin was selected as a parent peptide portion for designing the analogue.
-
FIG. 2 shows the amino acid sequences of hdMolluscidin, an antimicrobial peptide derived from abalone, and the parent peptide portion (fragment 1 and fragment 2) for designing the antimicrobial peptide analogue according to the present disclosure. - Because each of the fragment 1 (amino acid sequence: AATKPKKAGAEAAP) and the fragment 2 (amino acid sequence: KPAKKQTKKKP) does not exhibit amphiphilicity although it forms an α-helix structure, it is necessary to substitute some amino acids so that it can exhibit both hydrophobicity and hydrophilicity at the same time.
- If the antimicrobial peptide analogue exhibits amphiphilicity through the amino acid substitution, the hydrophilic part facilitates binding to the cell membrane or DNA and the hydrophobic part facilitates permeation.
- When designing the antimicrobial peptide analogue using the
fragment 1 or thefragment 2, it is desired that lysine (K), which is a hydrophilic (positively charged) residue, and alanine (A), which is a hydrophobic residue, are retained. Meanwhile, proline (P), threonine (T) and glutamine (Q), which are polar but not electrically charged, may be substituted with another hydrophobic residue, specifically a leucine (L) residue, because they are not desired in terms of antimicrobial activity. - In addition, tryptophan (W), which exhibits high membrane permeability and high resistance to proteases, may be located beside a residue vulnerable to the enzymes such as lysine (K) so as to reduce cutting by the proteases.
- The antimicrobial peptide analogue of the present disclosure is designed using the
fragment 1 or thefragment 2 as a parent peptide and may contain: a hydrophobic group containing 1-3 amino acid residues selected from alanine (A), leucine (L) and tryptophan (W); and a hydrophilic group containing 1 or 2 lysine (K) residue(s). Specifically, the number of the hydrophobic group may be 3 or 4 and the number of the hydrophilic group may be 2 or 3. Specifically, the hydrophobic group may be bound to 2 or more locations selected from a group consisting of the C-terminal and the N-terminal of the hydrophilic group and between hydrophilic groups. Specifically, the hydrophobic group may consist of 2 or less kinds of amino acid residues. - Specifically, the antimicrobial peptide analogue according to the present disclosure may consist of 8-15 amino acid residues. And, specifically, it may contain at least one amino acid sequence KLLK. If the peptide analogue contains the amino acid sequence ‘KLLK’, it is very advantageous in enhancing antimicrobial activity.
- Specifically, in the antimicrobial peptide analogue of the present disclosure, if the hydrophobic group is located between the hydrophilic group and the at least one hydrophilic group bound to the hydrophobic group comprises 2 lysine (K) residues, the number of amino acid residues of the hydrophobic group may be 2.
- Specifically, an amino group (—NH2) or a methyl group (—CH3) may be added to the C-terminal of the antimicrobial peptide analogue according to the present disclosure. If the C-terminal of the antimicrobial peptide analogue is amidated, resistance to proteases and positive net charge may be further enhanced. And, if it is methylated, in-vivo stability may be increased because resistance to exopeptidases, which cleave the peptide from the terminal, can be increased.
- Specifically, the peptide analogue may have an acetylated or palmitoylated N-terminal. If the N-terminal of the antimicrobial peptide analogue is acetylated, much superior antimicrobial activity can be achieved as compared to when it is not and the peptide can be protected from proteolytic degradation. And, if it is palmitoylated, permeability into cells can be enhanced.
- The antimicrobial peptide analogue according to the present disclosure exhibits antimicrobial activity and is commercially viable because it has a short amino acid sequence. In addition, the antimicrobial peptide analogue according to the present disclosure has strong inner membrane permeability. That is to say, it is likely that the antimicrobial peptide analogue according to the present disclosure exhibits antimicrobial activity by directly permeating into the inner membrane of bacteria. And, the antimicrobial peptide analogue according to the present disclosure lacks a cytotoxicity problem because it exhibits no hemolytic activity.
- The antimicrobial peptide analogue designed and prepared as described above may have antimicrobial activity against one or more selected from a group consisting of bacteria such as Gram positive bacteria, Gram negative bacteria, etc. and fungi such as yeast, molds, etc.
- More specifically, the antimicrobial peptide analogue may have antimicrobial activity against one or more selected from a group consisting of four species of Gram positive bacteria (Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus mutans and Propionibacterium acnes), five species of Gram negative bacteria (E. coli D31, E. coli ML35p, Shigella flexneri, Pseudomonas aeruginosa and Vibrio parahaemolyticus) and one yeast species (Candida albicans).
- The present disclosure also provides an antimicrobial pharmaceutical composition containing the antimicrobial peptide analogue according to the present disclosure as an active ingredient.
- A method for administering the pharmaceutical composition is not particularly limited. Specifically, it may be administered intraarterially, intravenously, subcutaneously, intrarectally, intranasally or via any other parenteral route. More specifically, it may be administered intraarterially, intravenously, orally or directly into muscle cells.
- The administration dosage of the composition will rely on the activity of the active ingredient, administration route, severity of the condition to be treated, condition and previous disease history of the patient. However, to start with a lower dosage than is required to achieve the desired therapeutic effect and gradually increase the administration dosage until the desired effect is achieved is within the knowledge of the related art and the specific administration dosage may be determined considering the age, sex, body type and body weight. The composition may be further processed before being formulated into a pharmaceutically acceptable pharmaceutical agent. Specifically, it may be pulverized or ground into smaller particles. For a desired effect, an effective dosage of the antimicrobial peptide of the present disclosure may be 1-2 mg/kg, specifically 0.5-1 mg/kg, and the administration may be made 1-3 times a day. However, the scope of the present disclosure is not limited by the administration dosage by any means.
- The pharmaceutical composition of the present disclosure may be prepared into a formulation of a unit dosage form or a multiple dosage form using a pharmaceutically acceptable carrier and/or excipient according to a method that can be easily employed by one of ordinary skill in the art to which the present disclosure belongs. The formulation may be an oral formulation such as a powder, a granule, a tablet, a capsule, a suspension, an emulsion, a syrup, an aerosol, etc., a formulation for external application such as an ointment, a cream, etc. or any other pharmaceutical formulation such as a suppository, a sterile solution for injection, etc. and may further contain a dispersant or a stabilizer.
- Because the antimicrobial peptide analogue exhibits antimicrobial activity against Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus mutans, Propionibacterium acnes, E. coli D31, E. coli ML35p, Shigella flexneri, Pseudomonas aeruginosa, Vibrio parahaemolyticus and Candida albicans, it can prevent or treat the diseases caused by them, such as food poisoning, candidiasis, typhoid, cholera, etc. Therefore, the antimicrobial peptide analogue may be used as an active ingredient in a pharmaceutical composition for preventing or treating the infectious diseases caused by the microorganisms.
- The antimicrobial peptide analogue may also be used as an active ingredient of an antimicrobial cosmetic composition. The cosmetic composition may be in the form of a solution, a powder, an emulsion, a lotion, a spray, an ointment, an aerosol, a cream or a foam. The cosmetic composition of the present disclosure may contain a carrier which is acceptable in a cosmetic formulation. The “carrier which is acceptable in a cosmetic formulation” refers to a compound or composition already used in cosmetic formulations or a compound or composition to be developed which lacks toxicity, instability or irritability as to be applicable to human skin.
- The carrier may be contained in an amount of about 1-99.99 wt %, specifically about 90-99.99 wt %, based on the total weight of the cosmetic composition of the present disclosure. Examples of the carrier may include an alcohol, an oil, a surfactant, a fatty acid, a silicone oil, a humectant, a moisturizer, a viscosity modifier, an emulsifier, a stabilizer, a sunscreen, a UV absorbent, a colorant, a fragrance, etc. A compound or composition that can be used as the alcohol, oil, surfactant, fatty acid, silicone oil, humectant, moisturizer, viscosity modifier, emulsifier, stabilizer, sunscreen, UV absorbent, colorant or fragrance is known in the art and can be adequately selected by those skilled in the art.
- In an exemplary embodiment of the present disclosure, the cosmetic composition according to the present disclosure may contain, in addition to the peptide analogue, glycerin, butylene glycol, propylene glycol, polyoxyethylene hydrogenated castor oil, ethanol, triethanolamine, etc. and may contain a trace amount of an antiseptic, a fragrance, a colorant, purified water, etc., if necessary.
- In the present disclosure, the term skin includes not only the face but also the scalp and the whole body. For application to the scalp, the cosmetic composition may be prepared as a shampoo, a rinse, a treatment, a hair restorer, etc. And, for application to the whole body, it may be prepared as a body cleanser, etc.
- The antimicrobial peptide analogue may also be used as an active ingredient of an antimicrobial food additive or a feed additive.
- In a specific exemplary embodiment of the present disclosure, the antimicrobial peptide according to the present disclosure can be usefully used in an antimicrobial food additive or a feed additive because it has superior antimicrobial activity against not only Gram negative and Gram positive bacteria but also fungi and lacks cytotoxicity.
- The food is not particularly limited in its kind. Examples of the food to which the substance can be added include a drink, a meat, a sausage, a bread, a biscuit, a rice cake, a chocolate, a candy, a snack, a pizza, an instant noodle, a noodle, a gum, a diary product including ice cream, a soup, a beverage, an alcoholic beverage, a vitamin supplement and any health functional food. The antimicrobial peptide analogue of the present disclosure may be added to a food as it is or as being mixed with other food or food ingredients. The mixing amount of the active ingredient may be determined adequately depending on the purpose of use (for prevention or improvement). In general, the antimicrobial peptide analogue may be added in an amount of 0.1-20 wt % based on the total weight of the food. However, when the composition is used for health or hygiene or it is used for a long time for the purpose of health control, the amount of the active ingredient may be smaller than the above-described range. Also, the amount of the active ingredient may be larger than the above-described range because it has no safety problem.
- In addition, the antimicrobial peptide analogue may be usefully used as an active ingredient of a hygiene product such as a wet wipe, a hand sanitizer, a mouthwash, an oral antiseptic or a toothpaste additive.
- Hereinafter, the present disclosure will be described in more detail through specific examples so that one or ordinary skill in the art to which the present disclosure belongs can easily carry out the present disclosure. However, the present disclosure can be embodied in various forms and is not limited by the examples.
- <Materials and methods>
- Reagents and materials
- Tryptic soy broth (TSB) and agarose type I (low EEO agar) for measurement of antimicrobial activity were purchased from Merck (Darmstadt, Germany) and Sigma (St. Louis, Mo, USA), respectively. Water and acetonitrile (CH3CN) for HPLC used in purification were purchased from Tedia (Ohio, USA). All other reagents were of analytical grade.
- Designing of Antimicrobial Peptide Analogue
- In order to design analogues of hdMolluscidin, its secondary structure was predicted using EMBOSS GUI's Gamier and ExPASy Tools' GOR as secondary structure prediction programs. Based on the predicted secondary structure of hdMolluscidin, two fragments exhibiting α-helix structures were selected at the N-terminal side to design the analogues.
- The designed analogues consisted of 8-15 amino acids. They were designed through amidation or methylation at the C-terminal, acetylation or palmitoylation at the N-terminal or addition, substitution, removal, etc. of amino acids at specific locations.
- Synthesis and Purification of Antimicrobial Peptide Analogue
- The designed peptide analogues were synthesized and purified by Peptron Inc. (Daejeon, Korea) to a purity of 95% or higher. The analogues were synthesized by F-moc solid-phase synthesis using the peptide synthesizer ASP48S (Peptron, Daejeon, Korea) and purified by RP-HPLC using the Shiseido Capcell-Pak C18 column (250 mm×4.6 mm, 10 μm). The purification was conducted at 220 nm with a flow rate of 1 mL/min using a H2O—CH3CN solvent system containing 0.1% (v/v) trifluoroacetic acid with a concentration gradient of 3-40%. The molecular weight of the purified peptide analogues was measured by liquid chromatography/mass spectrometry (LC/MS; HP1100 series; Agilent, Santa Clara, Calif., USA). The purified peptide analogues were dissolved in 0.01% acetic acid to a concentration of 1000 μg/mL and used in the following experiments.
- Method for Measuring Antimicrobial Activity and Used Microorganisms
- Four species of Gram positive bacteria (Bacillus subtilis, Staphylococcus epidermidis, Staphylococcus mutans and Propionibacterium acnes), five species of Gram negative bacteria (E. coli D31, E. coli ML35p, Shigella flexneri, Pseudomonas aeruginosa and Vibrio parahaemolyticus) and one yeast species (Candida albicans) were used for experiments. The antimicrobial activity was measured by ultrasensitive radial diffusion assay (URDA) using two layers of media of different concentrations. First, the microorganisms were pre-cultured in each medium for 18 hours and the concentration of the microorganisms was adjusted to 84% T (≈1×108 CFU/mL) using a colorimeter (Product No. 52-1210, BioMerieux, Inc., USA). Then, 0.5 mL of the diluted microorganism solution was added to an underlay gel containing 9.5 mL of 0.03% TSB, 1% type I agarose and 10 mM phosphate buffer (PB; pH 6.5) and plated and solidified on a plate after mixing well. After boring a well with a diameter of 2.5 mm on the solidified plate using a punch, 5 μL of each analogue solution was introduced. All the analogues were dissolved in 5 μL of 0.01% acetic acid to avoid any effect of solvent. After the analogue permeated into the medium, the microorganisms were cultured for 3 hours and an overlay gel containing 10 mL of 6% TSB, 1% type I agarose and 10 mM phosphate buffer (pH 6.5) was poured and solidified. Then, the microorganisms were cultured again for 18 hours at the same temperature. Next day, the antimicrobial activity was determined by measuring the size (diameter) of a clear zone formed around the well.
Piscidin 1, an antimicrobial peptide derived from the mast cells of a hybrid striped bass, was used as a control. - Measurement of Hemolytic Activity
- Hemolytic activity was measured using human red blood cells. After adding to human blood an equal amount of phosphate buffered saline (PBS, 50 mM sodium phosphate, 150 mM NaCl, pH 7.4), mixing and centrifuging at 8000×g and 4° C. for 1 minute, the supernatant was removed and the remaining red blood cells were washed 3 times. The red blood cells were added to PBS to a concentration of 3% hematocrit. In order to measure the hemolytic activity, 90 μL of the 3% hematocrit was introduced to an e-tube and then 10 μL of each analogue solution (×10) was added. After incubation of each e-tube at 37° C. for 1 hour, centrifugation was performed at 13,000×g and 4° C. for 10 minutes. After taking 70 μL from each supernatant and transferring to a 96-well microtiter plate, release of hemoglobin was measured at 405 nm. Triton X-100 (0.1%) was used as a control group for 100% lysis of red blood cells and the hemolytic activity was calculated according to the following equation.
-
% Hemolysis=[(Abs 405 nm in the peptide solution−Abs 405 nm in buffer)/(Abs 405nm in 0.1% Triton X-100−Abs 405 nm in buffer)]×100 - Measurement of Inner Membrane Permeability
- The inner membrane permeability was measured by measuring the activity of β-galactosidase present in the cytoplasm of E. coli ML35p using O-nitrophenyl-β-D-galactopyranoside (ONPG) as a non-membrane-permeative chromogenic substrate. Cultured E. coli ML35p in the mid-logarithmic phase was washed with 10 mM sodium phosphate buffer (NaPB, pH 7.4) and then dissolved in the same buffer containing 1.5 mM ONPG. Then, after adding the peptide analogue, the degree of hydrolysis of β-galactosidase released from the E. coli ML35p by the ONPG to O-nitrophenol was measured at 420 nm. Piscidin 1 and 0.01% acetic acid were used as control groups.
- Chromogenic Bacteriolytic Plate Assay
- In order to investigate the lytic activity of the analogues for bacterial membrane, chromogenic bacteriolytic plate assay was conducted using E. coli ML35p containing a chromosomal IPTG-inducible β-galactosidase gene (Mardones, G., Venegas, A. Chromogenic plate assay distinguishing bacteriolytic from bacteriostatic activity of an antibiotic agent. J Microbiol Methods. 2000, 40(3), 199-206). After inoculating 2 mL of E. coli ML35p to TSB and culturing at 37° C. for 16-18 hours, a mixture of 50 μL of the cultured microorganism solution, 10 μL of 1 mM IPTG and 50 μL of 50 mg/mL X-gal was poured onto TSB containing 0.8% agarose at 42° C. the next day. After boring a well on the solidified plate, 5 μL of each peptide analogue solution was introduced and incubation was conducted for 3 hours. Then, after pouring 2×TSB containing 10 mL of 1.5% agarose to the plate and solidifying, incubation was conducted again for 16-18 hours. After the incubation, the size (diameter) of a clearing zone and the presence or absence of a blue line at the edge portion were investigated.
- Measurement of Minimum Inhibitory Concentration (MIC)
- The minimum inhibitory concentration of the analogues was measured according to Patrzykat et al.'s method (Patrzykat, A., Gallant, J. W., Seo, J. K., Pytyck, J., Douglas, S. E. Novel antimicrobial peptides derived from flatfish genes. Antimicrob Agents Chemother. 2003, 47(8), 2464-2470). The peptide analogue solutions were prepared by continuous dilution using 100 μg/mL to 3.13 μg/mL of 0.01% HAc and the measurement was made using 96-well polypropylene microtiter plates (Costar; Corning Incorporated, Corning, N.Y., USA). E. coli ML35p used for the measurement was cultured in TSB medium for 16 hours up to the mid-logarithmic phase and then finally diluted to a concentration of 106 CFU/mL using TSB medium. In order to measure the minimum inhibitory concentration, 90 μL of the finally diluted microorganism solution was added to each well of a 96-well plate and then 10 μL of each analogue solution at a concentration of ×10 of the target concentration was added to each well. No analogue was added for a negative control group and
piscidin 1 was added for a positive control group. The minimum inhibitory concentration was defined as the concentration of the analogue when no growth of microorganisms was visually observed at all. In order to investigate the mechanism of the antimicrobial activity of the analogues, each analogue corresponding to the minimum inhibitory concentration was taken from the microorganism solution of each well and plated on a TSA plate. After culturing, it was investigated whether the mechanism is bacteriostatic or bactericidal by based on colony formation. - Killing Kinetics Study
- For killing kinetics study of the analogues whose bactericidal process was identified, killing rate for each analogue was investigated at 1×MIC and 5×MIC for 60 minutes. For this, the analogue was added to an e-tube containing 106 CFU/mL of E. coli ML35p. While incubating at 37° C., 10 μL of the solution was taken from the tube at predetermined times (5, 10, 20, 30, 40, 50 and 60 minutes after the addition of the analogue) and plated on a TSA plate. Then, the number of formed colonies was counted. As control groups, no analogue or
piscidin 1 was added. The killing % for the analogues was represented as the number of formed colonies relative to that when no analogue was added. - 1) hdMolluscidin
- hdMolluscidin, isolated from the gill of abalone (Haliotis discus), is an antimicrobial peptide consisting of 46 amino acids and having a molecular weight of 4767.2 Da. hdMolluscidin shows high sequence similarity to cgMolluscidin, an antimicrobial peptide derived from the gill of Pacific oyster (
FIG. 1 ).FIG. 1 shows a sequence alignment result of the amino acid sequences of hdMolluscidin and cgMolluscidin. InFIG. 1 , the conserved sequences are shown black. - In order to design analogues with shorter length and increased antimicrobial activity, the secondary structure of hdMolluscidin was predicted using a structure prediction program (
FIG. 2 ). - 2) Prediction of Secondary Structure of hdMolluscidin
- The secondary structure of hdMolluscidin was predicted using ExPASy Tools' GOR method. As a result, it was predicted that hdMolluscidin has a combination of α-helix and random structures (
FIG. 2 ). Based on this result, two portions (fragment 1 and fragment 2) toward the N-terminal exhibiting α-helix structure were selected as parent regions for designing analogues. - 3) Primary Structure of hdMolluscidin Analogues
- The peptide analogues designed based on the α-helix structure of hdMolluscidin toward the N-terminal are shown in Table 1. Each analogue consisted of 8-15 amino acid residues. The synthesized analogues were identified by measuring molecular weight.
-
TABLE 1 SEQ ID NO Peptide Sequence SEQ ID NO 1Ab2-2 AAWKLLKALAKA-NH2 SEQ ID NO 2Ab2-3 LLWKLLKLLLK-NH2 SEQ ID NO 3Ab2-4 LLWKLLKKLLK-NH2 SEQ ID NO 4 Ab2-5 LLWKLLKKL-NH2 SEQ ID NO 5Ab4-1 Ac-KLALKLLKLL-NH2 SEQ ID NO 6 Ab4-2 Ac-KAAAKAAKAA-NH2 SEQ ID NO 7 Ab4-3 KLLLKLLKLL-NH2 SEQ ID NO 8Ab4-4 KLLLKLLKKLL-NH2 SEQ ID NO 9 Ab4-5 KLLKKLLKLL-NH2 SEQ ID NO 10Ab4-7 KWLLKLLKKL-NH2 SEQ ID NO 11 Ab4-8 LKWLLKLLKLK-NH2 - The antimicrobial activity of the analogues and piscidin 1 (antimicrobial peptide derived from a hybrid striped bass) as a control antimicrobial peptide against bacteria and one yeast species was measured by the URDA method. As a result, the analogues of the present disclosure showed strong antimicrobial activity against the microorganisms. Among them, the antimicrobial peptide analogues having amino acid sequences of SEQ ID NO 4 (Ab2-5) and SEQ ID NO 10 (Ab4-7) showed the best antimicrobial activity (
FIG. 3 ). - In order to investigate the antimicrobial spectrum of the analogues, antimicrobial activity was measured for various microorganisms (Tables 2-4). As a result, the peptide analogues of the present disclosure showed antimicrobial activity comparable to that of
piscidin 1. In particular, they showed stronger antimicrobial activity against C. albicans thanpiscidin 1. - In addition, whereas the parent peptide hdMolluscidin showed little antimicrobial activity against C. albicans, the antimicrobial peptide analogues of the present disclosure showed strong antimicrobial activity against C. albicans.
-
TABLE 2 Minimal effective concentration (μg/mL) SEQ ID SEQ ID SEQ ID SEQ ID Microbe Gram NO 1 NO 2 NO 3 NO 4 Piscidin 1B. subtilis KCTC1021 + 20.0 16.0 14.0 5.8 7.5 S. epidermidis KCTC1917 + 17.3 18.4 17.2 5.6 NT S. mutans KCCM40105 + 20.3 16.3 15.8 5.5 3.2 Propionibacterium acnes KCTC11946 + 25.0 18.0 14.5 9.4 NT E. coli D31 − 22.0 16.2 19.4 13.5 3.8 E. coli ML35p − 23.0 12.1 13.8 8.4 2.3 Shigella flexneri KCTC2009 − 28.0 11.6 10.0 8.7 8.0 P. aeruginosa KCTC2004 − 36.0 14.2 15.2 10.7 8.0 Vibrio parahaemolyticus KCCM42264 26.3 14.0 9.1 5.3 3.0 C. albicans KCCM42264 Yeast 42.0 17.0 15.0 10.0 >62.5 -
TABLE 3 Minimal effective concentration (μg/mL) SEQ ID SEQ ID SEQ ID SEQ ID Microbe Gram NO 5 NO 6 NO 7 NO 8 Piscidin 1B. subtilis KCTC1021 + 15.2 >50.0 11.2 10.3 7.5 S. epidermidis KCTC1917 + 16.4 >50.0 8.8 9.6 NT S. mutans KCCM40105 + 10.5 >50.0 7.8 7.4 3.2 Propionibacterium acnes KCTC11946 + 16.6 >50.0 11.9 12.3 NT E. coli D31 − 17.5 >50.0 13.2 14.2 3.8 E. coli ML35p − 10.5 >50.0 8.8 9.8 2.3 Shigella flexneri KCTC2009 − 17.9 >50.0 10.4 10.7 8.0 P. aeruginosa KCTC2004 − 19.9 >50.0 11.2 12.5 8.0 Vibrio parahaemolyticus KCCM42264 8.1 >50.0 6.8 7.1 3.0 C. albicans KCTC7965 Yeast 14.4 >50.0 12.1 11.8 >62.5 -
TABLE 4 Minimal effective concentration (μg/mL) SEQ ID SEQ ID SEQ ID Piscidin Microbe Gram NO 9 NO 10 NO 11 1 B. subtilis KCTC1021 + 15.7 9.6 12.1 7.5 S. epidermidis KCTC1917 + 14.0 4.6 16.0 NT S. mutans KCCM40105 + 9.0 4.1 12.0 3.2 Propionibacterium acnes + 18.5 6.2 13.1 NT KCTC11946 E. coli D31 − 18.9 12.2 14.1 3.8 E. coli ML35p − 17.2 9.9 15.0 2.3 Shigella flexneri − 15.4 8.7 11.2 8.0 KCTC2009 P. aeruginosa KCTC2004 − 17.8 7.2 8.7 8.0 Vibrio parahaemolyticus 9.5 4.7 9.0 3.0 KCCM42264 C. albicans KCTC7965 Yeast 14.0 7.4 10.0 >62.5 - In order to investigate the toxicity of the hdMolluscidin analogues, the hemolytic activity of the analogues and
piscidin 1 as a control antimicrobial peptide against human red blood cells (blood type B) was measured. The peptide analogues of SEQ ID NO 4 andSEQ ID NO 10 showed good hemolytic activity (FIG. 4 ). - The peptide analogues of the present disclosure showed little hemolytic activity up to the concentration of 50 μg/mL. At the concentration of 100 μg/mL, SEQ ID NO 4 (Ab2-5) showed about 10% of hemolytic activity and SEQ ID NO 10 (Ab4-7) showed about 50% of hemolytic activity against human red blood cells. In contrast,
piscidin 1 showed strong hemolytic activity at 12.5 μg/mL. This result suggests that, unlikepiscidin 1 which has strong hemolytic activity, the analogues of the present disclosure show little toxicity against human red blood cells at effective concentrations (<50 μg/mL). - In order to investigate the permeability of the hdMolluscidin analogues and
piscidin 1 as a control antimicrobial peptide to the bacterial inner membrane, membrane permeability was measured for E. coli ML35p (FIG. 5 ). As a result,piscidin 1 showed strong inner membrane permeability for E. coli ML35p in a time-dependent manner. The analogues of the present disclosure also showed strong inner membrane permeability for E. coli ML35p in a time-dependent manner similarly topiscidin 1. - This result suggests that the hdMolluscidin analogues of the present disclosure are likely to exhibit antimicrobial activity by directly permeating into the bacterial inner membrane.
- In order to investigate the mechanism of antimicrobial activity of the analogues, chromogenic bacteriolytic plate assay was conducted using E. coli ML35p containing a chromosomal IPTG- inducible β-galactosidase gene (
FIG. 6 ). As a result, whereas the antibiotic streptomycin known to exhibit chromogenic bacteriolytic activity against E. coli ML35p showed a blue line at the edge portion, tetracycline known not to exhibit bacteriolytic activity showed no blue line at the edge portion.Piscidin 1 used as a control substance showed an edge line and the peptide analogues of the present disclosure of SEQ ID NO 4 (Ab2-5) and SEQ ID NO 10 (Ab4-7) also showed bacteriolytic activity because blue lines were observed at the edge portion. - This result suggests that the two analogues of the present disclosure lyse the bacterial membrane.
- Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) were measured in order to investigate whether the antimicrobial activity of the analogues is bacteriostatic or bactericidal. As a result, the peptide analogues of the present disclosure showed low MIC for E. coli ML35p similarly to piscidin 1 (Tables 5-7).
-
TABLE 5 Minimum inhibitory concentration (MIC) (μg/mL) SEQ ID SEQ ID SEQ ID SEQ ID Microbes Gram NO 1 NO 2 NO 3 NO 4 Piscidin 1E. coli − 50.0 25.0 25.0 12.5 12.5 ML35p -
TABLE 6 Minimum inhibitory concentration (MIC) (μg/mL) SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID Microbes Gram NO 5 NO 6 NO 7 NO 8 NO 9 E. coli − 25 >50 12.5 12.5 25 ML35p -
TABLE 7 Minimum inhibitory concentration (MIC) (μg/mL) Microbes Gram SEQ ID NO 10SEQ ID NO 11 E. coli ML35p − 6.25 25 - MBC was measured based on the MIC measurement. As a result, the analogues and
piscidin 1 showed the same MBC values as the MIC values (FIG. 7 , Tables 8-10). This result suggests that the minimum inhibitory concentration (MIC) of the peptide analogues of the present disclosure is identical to the minimum bactericidal concentration (MBC), which means that the antimicrobial activity is achieved through a bactericidal process. -
TABLE 8 Minimum bactericidal concentration (MBC) (μg/mL) SEQ ID SEQ ID SEQ ID SEQ ID Microbes Gram NO 1 NO 2 NO 3 NO 4 Piscidin 1E. coli − 50.0 25.0 25.0 12.5 12.5 ML35p -
TABLE 9 Minimum bactericidal concentration (MBC) (μg/mL) SEQ ID SEQ ID SEQ ID SEQ ID SEQ ID Microbes Gram NO 5 NO 6 NO 7 NO 8 NO 9 E. coli − 25 >50 12.5 12.5 25 ML35p -
TABLE 10 Minimum bactericidal concentration (MBC) (μg/mL) Microbes Gram SEQ ID NO 10SEQ ID NO 11 E. coli ML35p − 6.25 25.0 - In order to investigate the killing kinetics of the analogues with time, the analogues were incubated at 1×MIC and 5×MIC for 60 minutes with E. coli ML35p and then killing kinetics study was conducted (
FIG. 8 ). As a result, all the peptide analogues of the present disclosure killed E. coli ML35p within 5 minutes at the concentrations of 1×MIC and 5×MIC.Piscidin 1, which was used as a control substance, killed E. coli ML35p within 20 minutes at 1×MIC and within 5 minutes at 5×MIC. This result suggests that the peptide analogues of the present disclosure kill the bacteria very quickly (within 5 minutes) after contacting with the bacteria. Therefore, it is though that the analogues directly permeate into the inner membrane of the bacteria and kill them quickly by boring pores on the membrane. - <Result>
- In order to obtain new antimicrobial peptide analogues with shorter length and improved activity from a parent antimicrobial peptide with a known primary structure, the inventors of the present disclosure have designed and synthesized peptide analogues by solid-phase synthesis from hdMolluscidin, an antimicrobial peptide isolated from the gill of abalone. The peptide analogues of the present disclosure were prepared by selecting a parent region from the N-terminal of hdMolluscidin, applying substitution, addition or removal of amino acids and amidating or methylating the C-terminal and/or acetylating or palmitoylating the N-terminal. The peptide analogues of the present disclosure showed strong antimicrobial activity and exhibited little hemolytic activity for red blood cells at concentrations exhibiting antimicrobial activity. The analogues were demonstrated to directly bind to the membrane of bacteria and kill the bacteria by permeating into the inner membrane. The peptide analogues of the present disclosure are expected to be utilized as candidate substances for replacing existing antibiotics.
- Hereinafter, formulation examples of the peptide analogue of the present disclosure are described.
- <1-1> Powder
-
Peptide analogue of the present disclosure 20 mg Lactose 20 mg - A powder was prepared by mixing the above ingredients and filling in a sealed pouch.
- <1-2> Tablet
-
Peptide analogue of the present disclosure 10 mg Corn starch 100 mg Lactose 100 mg Magnesium stearate 2 mg - A tablet was prepared by mixing the above ingredients and tableting according to a commonly employed method.
- <1-3> Capsule
-
Peptide analogue of the present disclosure 10 mg Crystalline cellulose 3 mg Lactose 14.8 mg Magnesium stearate 0.2 mg - A capsule was prepared by mixing the above ingredients and filling in a gelatin capsule according to a commonly employed method.
- <1-4> Liquid
-
Peptide analogue of the present disclosure 20 mg Isomerized sugar 10 g Mannitol 5 g Purified water adequate - According to a commonly employed method, the above ingredients were added to and dissolved in purified water and an adequate amount of lemon flavor was added. After making the
final volume 100 mL by adding purified water, the resulting liquid was filled in a brown bottle and sterilized. - <1-5> Injection
-
Peptide analogue of the present disclosure 10 μg/mL Dilute HCl BP to pH 7.6 Sodium chloride BP up to 1 mL - The peptide analogue of the present disclosure was dissolved in an adequate volume of sodium chloride BP. After adjusting the pH of the resulting solution to pH7.6 using dilute HCl BP, the final volume was adjusted using sodium chloride BR After sufficient mixing, the resulting solution was filled in a 5-mL type I ampoule and the ampoule was sealed by melting. Then, an injection was prepared by sterilizing the solution in an autoclave at 120° C. for at least 15 minutes.
- <2-1> Softening lotion (skin lotion)
- An antibacterial softening lotion containing the peptide analogue of the present disclosure was prepared according to a commonly employed method as described in [Table 5].
-
TABLE 5 Ingredients Contents (wt %) Peptide analogue of the present disclosure 0.1-30% 1,3-Butylene glycol 3.0 Glycerin 5.0 Polyoxyethylene (60) hydrogenated castor oil 0.2 Ethanol 8.0 Citric acid 0.02 Sodium citrate 0.06 Antiseptic trace Fragrance trace Purified water To 100 - <2-2> Nourishing lotion (milk lotion)
- An antibacterial nourishing lotion containing the peptide analogue of the present disclosure was prepared according to a commonly employed method as described in [Table 6].
-
TABLE 6 Ingredients Contents (wt %) Peptide analogue of the present disclosure 0.1-30% 1,3-Butylene glycol 3.0 Glycerin 5.0 Squalane 10.0 Polyoxyethylene sorbitan monooleate 2.0 Guaiacum oil 0.1-30% Polyoxyethylene (60) hydrogenated castor oil 0.2 Ethanol 8.0 Citric acid 0.02 Sodium citrate 0.06 Antiseptic trace Fragrance trace Purified water To 100 - <2-3> Cleansing foam
- An antibacterial cleansing foam containing the peptide analogue of the present disclosure was prepared according to a commonly employed method as described in [Table 7].
-
TABLE 7 Ingredients Contents (wt %) Peptide analogue of the present disclosure 0.1-30% Sodium N-acylglutamate 20.0 Glycerin 10.0 PEG 400 15.0 Propylene glycol 10.0 POE (15) oleyl alcohol ether 3.0 Laurin derivative 2.0 Methyl paraben 0.2 EDTA-4Na 0.03 Fragrance 0.2 Purified water To 100 - <2-4> Nourishing cream
- An antibacterial nourishing cream containing the peptide analogue of the present disclosure was prepared according to a commonly employed method as described in [Table 8].
-
TABLE 8 Ingredients Contents (wt %) Peptide analogue of the present disclosure 0.1-30% Vaseline 7.0 Liquid paraffin 10.0 Beeswax 2.0 Polysorbate 60 2.5 Sorbitan sesquioleate 1.5 Squalane 3.0 Propylene glycol 6.0 Glycerin 4.0 Triethanolamine 0.5 Xanthan gum 0.5 Tocopheryl acetate 0.1 Flavor and antiseptic trace Purified water To 100 - While the present disclosure has been described with respect to the specific embodiments, it will be apparent to those skilled in the art that various changes and modifications may be made without departing from the spirit and scope of the disclosure as defined in the following claims.
Claims (17)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020160154215A KR101899552B1 (en) | 2016-11-18 | 2016-11-18 | Antimicrobial Peptide Analogues Derived From The Abalone, Haliotis Discus, And Antimicrobial Pharmaceutical Composition Containing The Same |
KR10-2016-0154215 | 2016-11-18 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20180141984A1 true US20180141984A1 (en) | 2018-05-24 |
US10077293B2 US10077293B2 (en) | 2018-09-18 |
Family
ID=62144810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/364,398 Active US10077293B2 (en) | 2016-11-18 | 2016-11-30 | Antimicrobial peptide analogues derived from abalone (Haliotis discus) and antimicrobial pharmaceutical composition containing the same |
Country Status (3)
Country | Link |
---|---|
US (1) | US10077293B2 (en) |
KR (1) | KR101899552B1 (en) |
WO (1) | WO2018092955A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111518189A (en) * | 2020-04-30 | 2020-08-11 | 大连理工大学 | Antimicrobial peptide MSPiscidin-3, and coding gene and application thereof |
CN112516283A (en) * | 2020-12-25 | 2021-03-19 | 威海长青海洋科技股份有限公司 | Quaternized abalone antibacterial peptide gel and preparation method and application thereof |
CN114014923A (en) * | 2020-10-27 | 2022-02-08 | 厦门大学 | Scylla paramamosain antibacterial polypeptide Sp-LECin and application thereof |
CN114106103A (en) * | 2022-01-24 | 2022-03-01 | 中国科学院南海海洋研究所 | Antibacterial peptide P-AMP108 from shellfish and application thereof in preparation of medicine for treating acne |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109042855A (en) * | 2018-08-30 | 2018-12-21 | 河南科技大学 | A kind of application of fruit and vegetable fresh-keeping agent and trypsase in terms of promoting candidiasis Biocontrol Effect |
EP3845072A4 (en) * | 2018-11-15 | 2021-09-08 | CJ Cheiljedang Corporation | Feed supplement for dairy cows comprising n-acetyl-l-tryptophan as effective component |
KR102148703B1 (en) * | 2019-02-20 | 2020-08-31 | 군산대학교 산학협력단 | Composition for improving skin wrinkle comprising peptides derived From Haliotis Discus as effective component |
CN110437303B (en) * | 2019-06-25 | 2021-01-05 | 中国农业科学院植物保护研究所 | Antibacterial peptide and application thereof |
KR102381481B1 (en) * | 2020-04-07 | 2022-04-01 | (주) 캠프테라퓨틱스 | Novel Antimicrobial Peptides Or Peptide Analogues And Use Thereof |
KR102385070B1 (en) * | 2020-06-29 | 2022-04-12 | 군산대학교 산학협력단 | Composition for preventing, improving, or treating inflammation comprising peptides derived From Haliotis Discus as effective component |
KR102518831B1 (en) * | 2020-09-16 | 2023-04-06 | 제주대학교 산학협력단 | Antibacterial peptide derived from Haliotis discus discus |
KR102540598B1 (en) * | 2021-04-13 | 2023-06-08 | 군산대학교 산학협력단 | Antibacterial peptide derived from Crassostrea gigas and its use |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040053847A1 (en) * | 2000-11-16 | 2004-03-18 | Yechiel Shai | Diastereomeric peptitdes and pharmaceutical compositions comprising them |
US20060062758A1 (en) * | 2004-09-21 | 2006-03-23 | Nastech Pharmaceutical Comapny Inc. | Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20000059465A (en) * | 1999-03-04 | 2000-10-05 | 허영섭 | Development and synthesis method of novel antimicrobial pseudopeptides |
CN101622271B (en) * | 2007-01-16 | 2014-08-27 | 加利福尼亚大学董事会 | Novel antimicrobial peptides |
KR101384578B1 (en) | 2012-03-27 | 2014-04-11 | 부경대학교 산학협력단 | Novel antimicrobial peptide from the Abalone,Haliotis discus discus,and uses thereof |
KR101422271B1 (en) | 2012-09-24 | 2014-07-24 | 건국대학교 산학협력단 | Peptide Isomers Possessing Antimicrobial and Anti-inflammatory Activities and Use of the Same |
-
2016
- 2016-11-18 KR KR1020160154215A patent/KR101899552B1/en active IP Right Grant
- 2016-11-21 WO PCT/KR2016/013413 patent/WO2018092955A1/en active Application Filing
- 2016-11-30 US US15/364,398 patent/US10077293B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040053847A1 (en) * | 2000-11-16 | 2004-03-18 | Yechiel Shai | Diastereomeric peptitdes and pharmaceutical compositions comprising them |
US20060062758A1 (en) * | 2004-09-21 | 2006-03-23 | Nastech Pharmaceutical Comapny Inc. | Tight junction modulator peptide PN159 for enhanced mucosal delivery of therapeutic compounds |
Non-Patent Citations (7)
Title |
---|
Infectious diseases, from http://www.mayoclinic.org/diseases-conditions/infectious-diseases/symptoms-causes/dxc-2..., pages 1-2, accessed 9/5/2017. * |
Kim et al, Disperse Distribution of Cationic Amino Acids on Hydrophilic Surface of Helical Wheel Enhances Antimicrobial Peptide Activity, Biotechnol. Bioeng., 2010, 107, pages 216-223. * |
Nordqvist, Infection: Types, causes, and differences, from http://www.medicalnewstoday.com/articles/196271.php, 8/22/2017, pages 1-19. * |
Search Result for SEQ ID NO: 6, from http://score.uspto.gov/...64398&seqId=09323b6782815e72&ItemName=20170901_165928_us-15-364-398a-6.rup&ItemType=4&startByte=0, pages 1-119, 9/1/2017. * |
Torri et al, A DNA Polymerase beta in the Mitochondrion of the Trypanosomatid Crithidia fasciculata, The Journal of Biological Chemistry, 1995, 270, pages 3495-3597. * |
Water, from http://www.biology-online.org/dictionary/Water, pages 1-3, accessed 4/24/2014. * |
Wierzbicki et al, Structure-Function Relationship in the Antifreeze Activity of Synthetic Alanine-Lysine Antifreeze Polypeptides, Biomacromolecules, 2000, 1, pages 268-274. * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111518189A (en) * | 2020-04-30 | 2020-08-11 | 大连理工大学 | Antimicrobial peptide MSPiscidin-3, and coding gene and application thereof |
CN114014923A (en) * | 2020-10-27 | 2022-02-08 | 厦门大学 | Scylla paramamosain antibacterial polypeptide Sp-LECin and application thereof |
CN112516283A (en) * | 2020-12-25 | 2021-03-19 | 威海长青海洋科技股份有限公司 | Quaternized abalone antibacterial peptide gel and preparation method and application thereof |
CN114106103A (en) * | 2022-01-24 | 2022-03-01 | 中国科学院南海海洋研究所 | Antibacterial peptide P-AMP108 from shellfish and application thereof in preparation of medicine for treating acne |
Also Published As
Publication number | Publication date |
---|---|
KR101899552B1 (en) | 2018-09-17 |
US10077293B2 (en) | 2018-09-18 |
KR20180056226A (en) | 2018-05-28 |
WO2018092955A1 (en) | 2018-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10077293B2 (en) | Antimicrobial peptide analogues derived from abalone (Haliotis discus) and antimicrobial pharmaceutical composition containing the same | |
KR101734064B1 (en) | Novel antimicrobial peptide derived from myxinidin peptide and uses thereof | |
KR20210007075A (en) | Novel antimicrobial peptide derived from antimicrobial peptides isolated from Korean sea cucumber and uses thereof | |
KR101595440B1 (en) | The effect of antimicrobial activity of CMA3 analogue peptide derived from CA-MA | |
US20170354177A1 (en) | Antifungal composition comprising antifungal peptide and terpene alcohol | |
CN111320678B (en) | Antibacterial peptide mutant and application thereof | |
KR102158036B1 (en) | Novel antimicrobial peptide derived from Pseudin-2 peptide and uses thereof | |
KR101905016B1 (en) | Antimicrobial Peptide Derived From The Mytilus coruscus And Its Use | |
EP1519951A2 (en) | Cationic linear peptides having antibacterial and/or antifungal properties | |
KR102243335B1 (en) | Antimicrobial peptide, Protaetiamycine 3 derived from protaetia brevitarsis seulensis and uses thereof | |
KR101998106B1 (en) | Novel antimicrobial peptide derived from Hp1404 peptide and uses thereof | |
KR102039400B1 (en) | Novel antimicrobial peptide derived from mBjAMP1 peptide and uses thereof | |
KR101980897B1 (en) | Novel antimicrobial peptide derived from LL37 peptide and uses thereof | |
KR101329223B1 (en) | Antimicrobial peptide with improved bioavailability and reduced cytoxicity and antimicrobial composition comprising the same | |
US20230303638A1 (en) | Peptide derived from pep27 peptide and uses thereof | |
KR102540598B1 (en) | Antibacterial peptide derived from Crassostrea gigas and its use | |
US8574556B2 (en) | Antibacterial pharmaceutical composition comprising Aceriphyllum rossii extract and active compounds isolated therefrom | |
KR102603281B1 (en) | Novel peptide derived from Hylin a1 peptide and uses thereof | |
KR102557375B1 (en) | Peptides Derived from Mitochondrial Presequence and Uses thereof | |
US11279737B2 (en) | Antimicrobial peptide variants and uses thereof | |
KR102243339B1 (en) | Antimicrobial peptide, Poecilocorisin 3 derived from Poecilocoris lewisi and uses thereof | |
WO2023048411A1 (en) | Novel antimicrobial peptide and use thereof | |
KR20190033839A (en) | Anti-inflammatory composition comprising macropin peptide as effective component | |
KR20230040783A (en) | Antimicrobial peptide, Protaetiamycine 10 derived from Protaetia brevitarsis seulensis and uses thereof | |
KR20230040655A (en) | Antimicrobial peptide, Protaetiamycine 7 derived from Protaetia brevitarsis seulensis and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KUNSAN N Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:SEO, JUNG-KIL;LEE, KI-YOUNG;CHO, SANG-MAN;AND OTHERS;SIGNING DATES FROM 20160125 TO 20161125;REEL/FRAME:040462/0980 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
AS | Assignment |
Owner name: KANU TECHNOLOGY HOLDINGS CO., LTD., KOREA, REPUBLI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KUNSAN NATIONAL UNIVERSITY;REEL/FRAME:048566/0912 Effective date: 20190227 |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |